Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +40.03%
#2 aelf aelf +33.32%
#3 Bitway Bitway +28.63%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.90%
#5 Starpower Starpower +20.64%
#6 Pons Pons +20.39%
#7 Decred Decred +14.50%
#8 PondCoin PondCoin +10.24%
#9 Talus Network Talus Network +9.61%
#10 MarsCoin MarsCoin +8.21%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
Classifica tra le azioni #30071
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Prezzo delle azioni
$0.00846342
Capitalizzazione di mercato
$20.02M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-47.56%
Paese
AU
Scambia Radiopharm Theranostics Limited (RAD)

Categoria

Healthcare
Utile per Radiopharm Theranostics Limited (RAD)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Radiopharm Theranostics Limited, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Radiopharm Theranostics Limited dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE